1. Scrip
  2. >>Focus On Asia
  3. >>India

US Price Control, Outcomes-Based Contracting: Reflections Of Former VA Secretary Shulkin

 
• By Anju Ghangurde

The former Secretary of the US Department of Veterans Affairs, David Shulkin, discusses in an interview with Scrip the US Inflation Reduction Act, telehealth,  interoperability of healthcare data, and Mark Cuban’s pharma venture.

David Shulkin, Former Secretary of the US Department of Veterans Affairs • Source: Shulkin Solutions

As pharma readies to deal with the landmark US Inflation Reduction Act (IRA), which establishes unprecedented powers for price controls in Medicare, a former government official asserts that industry is not likely to face a big financial hit but ought to address the issue of affordability in earnest or risk action.

In an interview with Scrip on his recent visit to India, David Shulkin, former Secretary of the US Department of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

Novo-Emcure Semaglutide Deal Clever Counter To Indian Rivals, Follows Lilly-Cipla Pact

 
• By Vibha Ravi

Novo Nordisk’s deal with Emcure for semaglutide will launch Poviztra as a second obesity brand in India, improving access to weight loss treatments following a Lilly-Cipla deal for tirzepatide and seems a clever counter to Indian majors planning to launch generic semaglutide next year

Aye Or Nay To Biosimilars For Sun Amid US Regulatory Easing?

 
• By Anju Ghangurde

Sun’s specialty gambit reaps gains with US sales surpassing generics for the first time in Q2 FY26, but will it finally enter the fray for biosimilars as the US moves to simplify regulatory requirements in the segment?

Aurobindo On Easier US Biosimilar Pathway, Zentiva Miss And Deal Strategy

 
• By Vibha Ravi

Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call

Outgoing Cipla CEO On Key Wins, Unfinished Agenda, Biosimilars ‘Explosion’ To Come

 
• By Anju Ghangurde

Cipla’s global CEO and MD Umang Vohra is moving on handing over the baton to global COO, Achin Gupta. Vohra talks about his innings, where he sees Cipla in 2030 and the impact of the latest FDA action that aims to make biosimilar development faster and less costly.

More from Focus On Asia

Aye Or Nay To Biosimilars For Sun Amid US Regulatory Easing?

 
• By Anju Ghangurde

Sun’s specialty gambit reaps gains with US sales surpassing generics for the first time in Q2 FY26, but will it finally enter the fray for biosimilars as the US moves to simplify regulatory requirements in the segment?

Aurobindo On Easier US Biosimilar Pathway, Zentiva Miss And Deal Strategy

 
• By Vibha Ravi

Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call

Korean Biosimilars Giants Step Up Race To Become Innovators

 
• By Jung Won Shin

South Korea’s two biosimilars giants have laid out differing strategies to pursue innovative drug R&D, although both are positioning ADCs as a core focus.